Peritoneal Cancer – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Peritoneal Cancer – Pipeline Review, H1 2018’, provides an overview of the Peritoneal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peritoneal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer

– The report reviews pipeline therapeutics for Peritoneal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Peritoneal Cancer therapeutics and enlists all their major and minor projects

– The report assesses Peritoneal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Peritoneal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Peritoneal Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Peritoneal Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3-V Biosciences Inc

AbbVie Inc

Adaptimmune Therapeutics Plc

Advenchen Laboratories LLC

Altor BioScience Corp

Amgen Inc

Arrien Pharmaceuticals LLC

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

AVEO Pharmaceuticals Inc

Bayer AG

BeiGene Ltd

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Caladrius Biosciences Inc

Celgene Corp

Celldex Therapeutics Inc

Celsion Corp

CerRx Inc

Chipscreen Biosciences Ltd

Clovis Oncology Inc

Cotinga Pharmaceuticals Inc

Dr. Reddy's Laboratories Ltd

Eisai Co Ltd

Eli Lilly and Co

EpiThany Inc

Epizyme Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Gene Techno Science Co Ltd

Genelux Corp

Genentech Inc

GlaxoSmithKline Plc

Glycotope GmbH

Gradalis Inc

Hemispherx Biopharma Inc

Ignyta Inc

ImmunoGen Inc

Immunovaccine Inc

Innate Pharma SA

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

Kazia Therapeutics Ltd

Kyowa Hakko Kirin Co Ltd

Lidds AB

MabVax Therapeutics Holdings Inc

Madrigal Pharmaceuticals Inc.

MaxCyte Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

Mersana Therapeutics Inc

Millennium Pharmaceuticals Inc

Mycenax Biotech Inc

NewLink Genetics Corp

Novartis AG

Oasmia Pharmaceutical AB

OBI Pharma Inc

Oncobiologics Inc

Oncoinvent AS

Oncolix Inc

Oncolytics Biotech Inc

OncoMed Pharmaceuticals Inc

Ono Pharmaceutical Co Ltd

Pfizer Inc

Pharma Mar SA

Plexxikon Inc

Polaris Pharmaceuticals Inc

Protheragen Inc

PsiOxus Therapeutics Ltd

PTC Therapeutics Inc

Richter Gedeon Nyrt

Rigel Pharmaceuticals Inc

Samyang Holdings Corp

Sanofi

Sanofi Pasteur SA

SELLAS Life Sciences Group Inc

Soricimed Biopharma Inc

Sotio AS

Sun Pharma Advanced Research Company Ltd

Syndax Pharmaceuticals Inc

TapImmune Inc

Tesaro Inc

Tyrogenex Inc

Vascular Biogenics Ltd

Verastem Inc

Vyriad Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Peritoneal Cancer Overview 8

Peritoneal Cancer Therapeutics Development 9

Peritoneal Cancer Therapeutics Assessment 26

Peritoneal Cancer Companies Involved in Therapeutics Development 43

Peritoneal Cancer Drug Profiles 86

Peritoneal Cancer Dormant Projects 966

Peritoneal Cancer Discontinued Products 970

Peritoneal Cancer Product Development Milestones 972

Appendix 984

List of Tables

List of Tables

Table 1: Number of Products under Development for Peritoneal Cancer, H1 2018

Table 2: Number of Products under Development by Companies, H1 2018

Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Table 6: Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Table 7: Number of Products under Development by Universities/Institutes, H1 2018

Table 8: Products under Development by Companies, H1 2018

Table 9: Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 10: Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Table 11: Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Table 12: Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Table 13: Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Table 14: Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Table 15: Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Table 16: Products under Development by Universities/Institutes, H1 2018

Table 17: Number of Products by Stage and Target, H1 2018

Table 18: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Table 19: Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018

Table 20: Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018

Table 21: Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018

Table 22: Number of Products by Stage and Mechanism of Action, H1 2018

Table 23: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Table 24: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018

Table 25: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018

Table 26: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018

Table 27: Number of Products by Stage and Route of Administration, H1 2018

Table 28: Number of Products by Stage and Molecule Type, H1 2018

Table 29: Peritoneal Cancer Pipeline by 3-V Biosciences Inc, H1 2018

Table 30: Peritoneal Cancer Pipeline by AbbVie Inc, H1 2018

Table 31: Peritoneal Cancer Pipeline by Adaptimmune Therapeutics Plc, H1 2018

Table 32: Peritoneal Cancer Pipeline by Advenchen Laboratories LLC, H1 2018

Table 33: Peritoneal Cancer Pipeline by Altor BioScience Corp, H1 2018

Table 34: Peritoneal Cancer Pipeline by Amgen Inc, H1 2018

Table 35: Peritoneal Cancer Pipeline by Arrien Pharmaceuticals LLC, H1 2018

Table 36: Peritoneal Cancer Pipeline by Astellas Pharma Inc, H1 2018

Table 37: Peritoneal Cancer Pipeline by Astex Pharmaceuticals Inc, H1 2018

Table 38: Peritoneal Cancer Pipeline by AstraZeneca Plc, H1 2018

Table 39: Peritoneal Cancer Pipeline by Atara Biotherapeutics Inc, H1 2018

Table 40: Peritoneal Cancer Pipeline by AVEO Pharmaceuticals Inc, H1 2018

Table 41: Peritoneal Cancer Pipeline by Bayer AG, H1 2018

Table 42: Peritoneal Cancer Pipeline by BeiGene Ltd, H1 2018

Table 43: Peritoneal Cancer Pipeline by Boehringer Ingelheim GmbH, H1 2018

Table 44: Peritoneal Cancer Pipeline by Boston Biomedical Inc, H1 2018

Table 45: Peritoneal Cancer Pipeline by Bristol-Myers Squibb Co, H1 2018

Table 46: Peritoneal Cancer Pipeline by Caladrius Biosciences Inc, H1 2018

Table 47: Peritoneal Cancer Pipeline by Celgene Corp, H1 2018

Table 48: Peritoneal Cancer Pipeline by Celldex Therapeutics Inc, H1 2018

Table 49: Peritoneal Cancer Pipeline by Celsion Corp, H1 2018

Table 50: Peritoneal Cancer Pipeline by CerRx Inc, H1 2018

Table 51: Peritoneal Cancer Pipeline by Chipscreen Biosciences Ltd, H1 2018

Table 52: Peritoneal Cancer Pipeline by Clovis Oncology Inc, H1 2018

Table 53: Peritoneal Cancer Pipeline by Cotinga Pharmaceuticals Inc, H1 2018

Table 54: Peritoneal Cancer Pipeline by Dr. Reddy's Laboratories Ltd, H1 2018

Table 55: Peritoneal Cancer Pipeline by Eisai Co Ltd, H1 2018

Table 56: Peritoneal Cancer Pipeline by Eli Lilly and Co, H1 2018

Table 57: Peritoneal Cancer Pipeline by EpiThany Inc, H1 2018

Table 58: Peritoneal Cancer Pipeline by Epizyme Inc, H1 2018

Table 59: Peritoneal Cancer Pipeline by Exelixis Inc, H1 2018

Table 60: Peritoneal Cancer Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Table 61: Peritoneal Cancer Pipeline by Fate Therapeutics Inc, H1 2018

Table 62: Peritoneal Cancer Pipeline by Gene Techno Science Co Ltd, H1 2018

Table 63: Peritoneal Cancer Pipeline by Genelux Corp, H1 2018

Table 64: Peritoneal Cancer Pipeline by Genentech Inc, H1 2018

Table 65: Peritoneal Cancer Pipeline by GlaxoSmithKline Plc, H1 2018

Table 66: Peritoneal Cancer Pipeline by Glycotope GmbH, H1 2018

Table 67: Peritoneal Cancer Pipeline by Gradalis Inc, H1 2018

Table 68: Peritoneal Cancer Pipeline by Hemispherx Biopharma Inc, H1 2018

Table 69: Peritoneal Cancer Pipeline by Ignyta Inc, H1 2018

Table 70: Peritoneal Cancer Pipeline by ImmunoGen Inc, H1 2018

Table 71: Peritoneal Cancer Pipeline by Immunovaccine Inc, H1 2018

Table 72: Peritoneal Cancer Pipeline by Innate Pharma SA, H1 2018

Table 73: Peritoneal Cancer Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018

Table 74: Peritoneal Cancer Pipeline by Johnson & Johnson, H1 2018

List of Figures

List of Figures

Figure 1: Number of Products under Development for Peritoneal Cancer, H1 2018

Figure 2: Number of Products under Development by Companies, H1 2018

Figure 3: Number of Products under Development by Universities/Institutes, H1 2018

Figure 4: Number of Products by Top 10 Targets, H1 2018

Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018

Figure 6: Number of Products by Top 10 Mechanism of Actions, H1 2018

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Figure 8: Number of Products by Top 10 Routes of Administration, H1 2018

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Figure 10: Number of Products by Top 10 Molecule Types, H1 2018

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports